Sections
| Title | Starting Page | Number of Pages |
|---|
| Cover | 1 | 6 |
| CONTENTS | 7 | 2 |
| Chapter 1 | 9 | 34 |
| The State of the Biotechnology Industry Today | 9 | 5 |
| A Short History of Biotechnology | 14 | 1 |
| Ethanol Production Soared, But a Market Glut May Slow Expansion | 15 | 3 |
| Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms | 18 | 1 |
| From India to Singapore to Australia, Nations Compete Fiercely in Biotech Development | 19 | 2 |
| Medical Trials Conducted Abroad Spark Concerns | 21 | 1 |
| Gene Therapies and Patients Genetic Profiles Promise a Personalized Approach to Medicine | 21 | 2 |
| Breakthrough Drugs for Cancer Treatment Many More Will Follow | 23 | 1 |
| Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues | 24 | 2 |
| Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age | 26 | 1 |
| Biogenerics (Follow-on Biologics) are in Limbo in the U.S. | 27 | 1 |
| Breakthrough Drug Delivery Systems Evolve | 28 | 1 |
| Stem Cells Multiple Sources Stem from New Technologies | 29 | 2 |
| U.S. Government Stance on Funding for New Stem Cell Research Unclear | 31 | 1 |
| Stem Cells Therapeutic Cloning Techniques Advance | 32 | 1 |
| Stem Cells A New Era of Regenerative Medicine Takes Shape | 33 | 1 |
| Nanotechnology Converges with Biotech | 34 | 1 |
| Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise | 35 | 3 |
| Focus on Vaccines | 38 | 1 |
| Ethical Issues Abound | 39 | 1 |
| Technology Discussion Genomics | 39 | 1 |
| Technology Discussion Proteomics | 40 | 1 |
| Technology Discussion Microarrays | 40 | 1 |
| Technology Discussion DNA Chips | 40 | 1 |
| Technology Discussion SNPs ( Snips ) | 41 | 1 |
| Technology Discussion Combinatorial Chemistry | 41 | 1 |
| Technology Discussion Recombinant DNA | 42 | 1 |
| Technology Discussion Polymerase Chain Reaction (PCR) | 42 | 1 |
| Chapter 2 | 43 | 25 |
| Biotech Industry Overview | 44 | 1 |
| The U.S. Drug Discovery &Approval Process | 45 | 1 |
| U.S. FDA New Drug and Biologic Approvals, 2009 | 46 | 1 |
| U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2009 | 47 | 1 |
| Employment in Life &Physical Science Occupations by Business Type, U.S.: May 2009 | 48 | 1 |
| Federal R&D &R&D Plant Funding for General Science &Basic Research, U.S.: Fiscal Years 2008-2010 | 49 | 1 |
| National Health Expenditure Amounts by Type of Expenditure, U.S.: Selected Calendar Years, 2004-2019 | 50 | 1 |
| U.S. Exports &Imports of Pharmaceutical Products: 2005-1st Quarter 2010 | 51 | 1 |
| U.S. Prescription Drug Expenditures, Aggregate &PerCapita Amounts, Percent Distribution: Selected Calendar Years, 2004-2019 | 52 | 1 |
| U.S. Prescription Drug Expenditures: 1965-2019 | 53 | 2 |
| Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2009 | 55 | 1 |
| Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Year 2009-2011 | 56 | 1 |
| Global Area of Biotech Crops by Country: 2009 | 57 | 1 |
| R&D as a Percentage of U.S. Biopharmaceutical Sales, PhRMA Member Companies: 1970-2009 | 58 | 1 |
| Biologics &Biotechnology R&D, PhRMA Member Companies: 2008 | 59 | 1 |
| Domestic &Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2009 | 60 | 1 |
| Sales By Geographic Area, PhRMA Member Companies: 2008 | 61 | 1 |
| Domestic U.S. Biopharmaceutical R&D Breakdown, PhRMA Member Companies: 2008 | 62 | 1 |
| R&D by Global Geographic Area, PhRMA Member Companies: 2008 | 63 | 1 |
| Domestic Biopharmaceutical R&D Scientific, Professional &Technical Personnel by Function, PhRMA Member Companies: 2008 | 64 | 1 |
| Domestic U.S. Biopharmaceutical R&D &R&D Abroad, PhRMA Member Companies: 1970-2009 | 65 | 3 |
